| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 7, 2017
PORTSMOUTH, N.H., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Medtronic (NYSE:MDT), a global medical device company with offices at the Pease Tradeport in Portsmouth, has been named the Best Company to...
-
Sep 5, 2017
DUBLIN - September 5, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the 2017 Wells Fargo Healthcare Conference on Thursday,...
-
Aug 28, 2017Published Simultaneously in The Lancet, the Late-Breaking SPYRAL HTN-OFF MED Study at ESC Successfully Isolates RDN Treatment Effect to Show Compelling Efficacy and Safety of Hypertension Procedure
DUBLIN and BARCELONA - August 28, 2017 - Medtronic plc (NYSE:MDT) today announced its intent to move forward with a new renal denervation pivotal trial following positive first results from a...
-
Aug 22, 2017Revenue of $7.390 Billion Grew 3% as Reported; 4% at Constant Currency
DUBLIN - August 22, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2018, which ended July 28, 2017. The company reported first quarter...
-
Aug 17, 2017
DUBLIN - August 17, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the CFA Society Minnesota's 6th Annual Investor Conference,...
-
Aug 15, 2017
DUBLIN - August 15, 2017 - Medtronic plc (NYSE: MDT) announced today that it will report financial results for the first quarter fiscal year 2018 on Tuesday, August 22, 2017. A news release will...
-
Aug 2, 2017Introduction of New Pericardial Aortic Heart Valve in the U.S. and Europe Reinforces Company's Commitment to Comprehensive Solutions to Heart Valve Disease
DUBLIN - August 2, 2017 - Medtronic plc (NYSE: MDT) today announced CE (Conformité Européenne) mark and U.S. Food and Drug Administration (FDA) approval of its new Avalus(TM) pericardial aortic...
-
Aug 1, 2017Data from Landmark Trial Published in the Journal of the American Heart Association
DUBLIN - August 1, 2017 - A new health economic analysis from the landmark FIRE AND ICE Trial, sponsored by Medtronic plc (NYSE: MDT), was published today in the Journal of the American Heart...
-
Jul 17, 2017The InterStim System is the Only Proven, Long-Term Sacral Neuromodulation Solution for Overactive Active Bladder
DUBLIN - July 17, 2017 - Medtronic plc (NYSE: MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of...
-
Jun 18, 2017Data Presented as Late Breaking Clinical Trial at EUROPACE 2017
DUBLIN and VIENNA - June 18, 2017 - Continuing its leadership in the detection, reduction, and treatment of atrial fibrillation (AF), Medtronic plc (NYSE: MDT) today announced that its Reactive...